Clinical trial
A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC…
NCT00190489 · Japan Clinical Oncology Group, Other · Completed
Key facts
| NCT number | NCT00190489 |
|---|---|
| Title | A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer |
| Official title | Phase III Trial of Doxorubicin /Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D (AC-D) as Front-line Chemotherapy for Metastatic Breast Cancer: Japan Clinical Oncology Group Trial (JCOG9802) |
| Lead sponsor | Japan Clinical Oncology Group, Other |
| Collaborators | Ministry of Health, Labour and Welfare, Japan |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles, Docetaxel 60mg/m2 every 21 days for 6 cycles, AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles |
| Enrollment | 450 |
| Start date | Jan 1, 1999 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Sep 2, 2016 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: